Adds share movement in paragraph 2, disease background in paragraph 3, trial details in paragraphs 4-5
Jan 15 (Reuters) - Keros Therapeutics KROS.O said on Wednesday it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.
Its shares fell 8% to $11.52 in premarket trading.
The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension — a rare, progressive lung disease that causes high blood pressure in the pulmonary arteries.
Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.
The company expects to present clinical data from the trial in the second quarter of 2025.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。